Vaxcyte (PCVX) Income towards Parent Company (2019 - 2026)

Vaxcyte (PCVX) has reported Income towards Parent Company for 8 consecutive years, with -$322.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 113.95% year-over-year to -$322.9 million; the TTM figure through Mar 2026 stood at -$1.3 billion (down 160.47% YoY), while the FY2025 annual figure was -$1.4 billion, down 60.03% from the prior year.
• Income towards Parent Company rose to -$322.9 million in Q1 2026 per PCVX's latest filing, from -$378.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$79.9 million in Q4 2022 and bottomed at -$455.9 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$224.2 million across 5 years, with a median of -$179.1 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company sank 380.33% — and 2025, when it surged 66.89%.
• Vaxcyte's Income towards Parent Company stood at -$79.9 million in 2022, then sank by 124.05% to -$179.1 million in 2023, then surged by 34.51% to -$117.3 million in 2024, then sank by 222.39% to -$378.2 million in 2025, then advanced by 14.61% to -$322.9 million in 2026.
• Business Quant data shows PCVX's Income towards Parent Company at -$322.9 million in Q1 2026, -$378.2 million in Q4 2025, and -$331.1 million in Q3 2025.